. 2019 May 7;104(9):4024–4032. doi: 10.1210/jc.2019-00073

Table 3.

Association of Impaired Fasting Glucose vs Normoglycemia With Outcomes [Excluding Patients With Fasting Plasma Glucose Level ≥126 mg/dL (≥7.0 mmol/L) at Baseline]

Outcome	Normoglycemia	Impaired Fasting Glucose	Unadjusted Hazard Ratio	Adjusted Hazard Ratio^a
Outcome	No. of Events/No. at Risk (%)		Unadjusted Hazard Ratio	Adjusted Hazard Ratio^a
Composite adverse renal outcome^b	314/5424 (5.8)	198/3602 (5.5)	0.93 (0.78–1.12)	0.94 (0.78–1.14)
Worsening kidney function^c	114/5424 (2.1)	70/3602 (1.9)	0.88 (0.65–1.19)	0.98 (0.72–1.34)
Incident albuminuria^d	203/2691 (7.5)	133/1796 (7.4)	0.98 (0.78–1.23)	0.96 (0.76–1.21)

^{^a}

Adjusted model: age, sex, race, smoking status, systolic blood pressure, prior cardiovascular disease, body mass index, statin use, aspirin use, and trial treatment arm.

^{^b}

Defined by worsening kidney function or incident albuminuria.

^{^c}

In participants without CKD at baseline, worsening kidney function was defined by a decrease in the eGFR of 30% or more to a value of <60 mL/min/1.73 m². In participants with CKD at baseline, worsening kidney function was defined by a decrease in the eGFR of 50% or more or the development of ESRD requiring long-term dialysis or kidney transplantation.

^{^d}

Defined for all study participants by a doubling of the ratio of urinary albumin/creatinine from <10 mg/g at baseline to >10 mg/g during follow-up.